Summary.-An in vitro chemosensitivity test has been applied to malignant melanoma cells from 5 patients. The tumour cells were first grown as xenografts in immune-suppressed mice, so that the results of the in vitro test could be compared with precise measurements of the sensitivity of the melanoma cells when exposed to chemotherapeutic drugs in vivo in the mouse. The in vitro assay involved exposing the tumour cells to each of 8 drugs, after which cell survival was determined by colony assay in soft agar. Dose-response curves were obtained and the surviving fraction at drug levels estimated to be achieved in man was used as a measure of in vitro drug sensitivity. Significant differences among the 8 drugs were detected, and these accorded with clinical experience. The correlation of in vivo (in the mouse) and in vitro sensitivities to Melphalan and MeCCNU was also significant.
Summary.-An in vitro chemosensitivity test has been applied to malignant melanoma cells from 5 patients. The tumour cells were first grown as xenografts in immune-suppressed mice, so that the results of the in vitro test could be compared with precise measurements of the sensitivity of the melanoma cells when exposed to chemotherapeutic drugs in vivo in the mouse. The in vitro assay involved exposing the tumour cells to each of 8 drugs, after which cell survival was determined by colony assay in soft agar. Dose-response curves were obtained and the surviving fraction at drug levels estimated to be achieved in man was used as a measure of in vitro drug sensitivity. Significant differences among the 8 drugs were detected, and these accorded with clinical experience. The correlation of in vivo (in the mouse) and in vitro sensitivities to Melphalan and MeCCNU was also significant. THE DESIRABILITY of developing in vitro tests for the sensitivity of human tuniours to chemotherapeutic agents is widely appreciated. There are 3 main difficulties in achieving a valid test. Firstly, human tumour cells when removed from the patient, dispersed, and set up in tissue culture, are no doubt damaged and modified by this procedure; their sensitivity to chemotherapeutic agents may therefore be modified. Secondly, it is very difficult in tissue culture to achieve the same total exposure to active drug metabolites as is produced by the in vivo treatment of tumours. Thirdly, it is difficult to choose aIn end-point for the in vitro assessment of cell death that can be relied upon accurately to reflect in vivo cell death. These are serious obstacles, but the potential advantages of in vitro chemosensitivity tests are such that it seems justifiable to seek to establish them even before our understanding of cell biology and pharmacodynamics allows the obstacles to be removed.
The attempt to validate an empirically designed chemosensitivity test faces the further obstacle that the objective assess-14 ment of the chemotherapeutic response of patients is often difficult, and lack of correlation with the results of the test may reflect undocumented variation in clinical staging and patient assessment rather than the failure of the test reliably to reflect cellular chemosensitivity. In face of this, we have taken the strategy of first seeking an in vitro test that will reliably reflect the chemosensitivity of human tumours grown as xenografts in immune-suppressed mice. The in vivo response of the xenografts can be accurately measured by cell-cloning assays and an in vitro colony assay can also be used as the end The present work comprises our second series of experiments in this project. In the first (Bateman et al., 1979) we demonstrated that the in vitro sensitivity of the cells of a human pancreatic carcinoma xenograft (HX32) to a range of drugs correlated well with their in vivo sensitivity in the mouse. The experiments recorded here were made possible by the establishment of a range of xenografts of human malignant melanoma and an extensive study of their in vivo chemosensitivity (Selby et al., 1980, and in preparation) . The objective was to examine variation in in vitro chemosensitivity among 5 melanoma xenografts, and where possible to compare the results with their in vivo chemosensitivity.
MATERIALS AND METHODS
Xenografts were established from 5 patients with malignant melanoma. Male CBA/lac mice were thymectomised at 4 weeks of age, and 2 weeks later they received cytosine arabinoside followed by 900 R whole-body radiation. This technique of immune suppression has been described by Steel et al. (1978) . Small pieces of tissue from biopsy specimens were then implanted bilaterally into the flanks of the mice. Tumours were subsequently passaged by the implantation of cell suspensions into the gastrocnemius muscles of immune-suppressed mice and were used experimentally when the leg diameters were 8-10 mm. Detailed studies by cytogenetics, immuno-fluorescence and electron microscopy confirmed that the xenografts retained the characteristics of human melanoma (Selby et al., 1980 medium plus rat red blood cells as described by Courtenay & Mills (1978) . Heavily irradiated tumour cells of the same type wvere added where necessary to make the total cell count up to 104/ml.
One-ml agar cultures containing 500-1,500 control cells or 1,500-30,000 treated cells were gassed with 500 02, 50o C02, 900% N2, and fed at 7-day intervals with 1-5 ml fresh medium. Colonies exceeding -50 cells were scored after 4 weeks. The in vitro plating efficiencies (PE) of control cells for the 5 tumours are summarised in Table I . The ratio of PE of treated cells to the PE of control cells was taken to be the fraction of clonogenic cells surviving treatment. At least 2 experiments were performed on each drug-tumour combination. Each experiment used 3 or more tubes per point. The total number of colonies scored varied w%videly betwveen experiments and between treatment groups; in control cultures, and in most treatment groups, it was between 50-150 colonies, but in some cases the total counts ranged up to 500 and down to 10. Typically, the standard error of surviving fraction estimates Aas about 5%, of the mean, but for some low values in lines HX50 and 52 it was as high as 15%. As can be seen from the charts, interexperiment variation usually exceeded these counting errors.
In vivo chemotherapeutic response was assessed by treating mice bearing subcutaneous tumours wvith single doses of cytotoxic agents up to the approximate LD1o values, and assessing the response in terms of the survival of colony-forming tumour cells. The Agar Diffusion Chamber (ADC) assay described by Smith et al. (1976) was used for this part of the study. Cell suspensions were prepared and suspended in 0-3 00 agar in Ham's F12 medium. The soft agar was intro- (Selby et al., 1980) . Values for these levels and the sources of the data are given in Table II of our previous paper (Bateman et al., 1979) and in Tables II and III Tables II and III. Analysis of variance was performed using the logarithm of surviving fraction as the response variable. At Level A there was no significant difference between the tumours (P > 0.05) but the differences between drugs were highly significant (P < 0 01). Newman and Keul's method was then used to test for difference between the drug means. The average log- (Table II) ; A at Level B (Table III) .
RESULTS

Comparison of in
in Fig. 5 , where it can be seen that at this level Melphalan, MeCCNU and cis-Pt were considerably more effective than the other agents. Differences amongst these 3 drugs were not significant, nor were differences amongst the other 5 drugs. However, any of the 3 most effective agents was sig-A nificantly more effective than any of the 5 (P<001). When this analysis was repeated at Level B it was again found that the tumours were not significantly different. The apparent change in the ranking of the 3 most effective drugs was not significant, but the relative increase in effectiveness of adriamycin made it significantly more effective than the 2 lowest-ranking agents. The 3 top-ranking agents were again significantly more effective than any of the 4 lowest-ranking drugs.
Since in Tables II and III there is only one value for the response of each tumour to each drug it is not possible to use these data to comment on differences in spectrum of drug response amongst the tumour lines. We therefore selected the 4 most effective drugs and read off from Figs 1-4 the individual surviving fractions (SF) that were recorded at a drug level close to Level A: i.e. at 1-0 Hug/ml for melphalan, 3-0 Htg/ml for MeCCNU, 2-3 ,ug/ml for cis-Pt, and 0 3 jug/ml for adriamycin. This yielded between 1 and 4 SF values for each of the tumour-drug combinations, and these were assumed to be independent. Analysis of variance was repeated on these data, looking for interactions in tumour response. It was found that the differences amongst the 4 drugs and amongst the 5 tumour lines were both significant (P< 0.01) as was the interaction (P < 0 01).
Tests showed no evidence for nonnormality in the data. We may therefore conclude that in response to the 4 most effective drugs there was evidence not only for differences in responsiveness amongst the tumour lines but also for differences in their spectrum of response to the drugs.
The growth rate of the 5 melanoma lines was very similar in vivo, each taking about 4 weeks to reach an 8mm leg diameter. Colonies could be scored after the samne culture period in vitro (4 weeks) and the colony growth rate was therefore also uniform. The main biological difference found amongst the lines was in melanin content. HX41 was highly melanotic, HX34, 47 and 52 were moderately melanotic, and HX50 was macroscopically amelanotic, though positive for Dopaoxidase activity.
Comparison of in vitro and in vivo drug sensitivity
Studies of cell survival after in vivo treatment were performed and completed before the investigations of in vitro sensitivity began. They were, therefore, performed on earlier passages of the xenografts. Values of surviving fraction were then read off from the survival curves at the LD10 dose levels, with extrapolation in the case of HX34 treated with MeCCNU.
The in vivo work used 4 drugs: mel- Fig. 6 . For each of the 3 drugs there is a positive correlation between in vitro and in vivo sensitivity, and for MeCCNU this is statistically significant. However, in the case of adriamycin the in vivo responses were so small (SF often statistically indistinguishable from 1.0) that the apparent positive correlation is probably fortuitous; the only point of significance mnay be that HX34 gave the greatest cell kill for adriamycin in vivo and stood out as the most sensitive tumour in vitro (Fig. 3) . The broken line in Fig. 6 indicates the condition where the surviving fraction in vivo equals that in vitro. The melphalan data lie fairly close to this line. For MeCCNU 2 of the tumours gave points well away from the line, one high, one low. For adriamycin we conclude that the drug was effective in vitro but ineffective in vivo.
Some studies of in situ tumour-growth delay were performed by exposing mice bearing 0-2 cm3 tumours to a single LD10 dose. Growth curves for treated and control animals were constructed from caliper measurements, and the median time taken for the tumours to double in volume was calculated. When the growth delay was calculated in multiples of the time to double of the controls, it was found that the results were mostly consistent with the cell-survival studies (Table IV) : HX47 treated with MeCCNU showed the greatest delay (5.0), compared with 1J0 for HX41 with MeCCNU. In HX41 melphalan showed as expected a greater growth delay (2.5) than MeCCNU. Adriamycin gave no growth delay for HX47, but its delay in HX41 (1.5) was longer than would have been expected on the basis of cell survival. We conclude that although the growth-delay studies were not sufficiently comprehensive to allow us to draw precise conclusions, there was a hint of a positive correlation with in vitro chemosensitivity in the ranking of MeCCNU and melphalan: HX47 (MeCCNU) > HX41 (melphalan) > HX41 (MeCCNU).
DISCUSSION
The data presented here are interesting from 2 points of view: in demonstrating that in a small group of xenograft lines an in vitro chemosensitivity test appeared to give some indication of their in vivo response, and in providing new evidence on the spectrum of drug sensitivity of individual human tumours.
The decision to base the ranking of the drug sensitivities in vitro on estimates of drug levels achieved in man (rather than in the mouse) was because of the availability of reliable plasma-clearance data in man and the fact that correlation with tumour response in man is the ultimate objective. This was a difficult choice, and it complicates the interpretation of the data shown in Table IV and Fig. 6 . It may well be, however, that differences in plasma levels between man and mouse have less effect on the results than other factors that limit the ability of an in vitro test to reflect in vivo tumour response. Drug access into the tumours is one such factor. A study of the access of 14C-melphalan into pancreatic carcinoma xenografts (HX32) showed that 60 min after injection the concentration of 14C in the tumour reached that in the blood (Selby, et al., unpublished) . No doubt some of this radioactivity was by then attached to metabolites of melphalan, but nevertheless the implication is that drug access was good. In contrast, we found in mice bearing the HX34 tumour that 18 h after an LD10 dose of adriamycin the level in liver was 0-9 /g/g but the level in the tumour was undetectable (confirming Siemann & Sutherland, 1979) . This result would support the view that the lack of in vivo effectiveness of adriamycin was partly attributable to poor drug access into solid tumours. The insensitivity of cells exposed in diffusion chambers might also be attributable to poor drug access. In further investigations we intend to evaluate in vitro sensitivity at drug levels achievable in tumours.
In parallel with the in vivo results reported here, studies were made ofthe survival of melanoma xenograft cells exposed to drugs within Millipore diffusion chambers (Selby, in preparation) . The chambers were removed from the treated mouse to a preirradiated recipient 18 h after treatment, and colonies were scored at 21 days. This "agar diffusion chamber (ADC) exposure" assay has the advantage that since drug treatment is in the mouse it is possible to use drugs that require metabolic activation. In the present work the in vivo and ADC exposure assays agreed reasonably well. Surprisingly, the ADC exposure results did not correlate better than the in vivo assay, with the in vitro assay.
The concept that human tumours are to some extent individual in their responsiveness to cytotoxic drugs is an important one. At present cancer chemotherapy is based on the classification of tumours by histopathological and staging criteria, each group of diseases then being treated by those drugs or drug combinations that are thought to be most effective. Clinical trials are designed to identify for each group the cytotoxic agents that give the best average result. It is a matter of common clinical experience that drugs which seem effective in one patient may not be so for another, but direct evidence for this has been difficult to obtain. The development of xenografts allows tissue taken from a particular patient to be testedin response to a wide range of drugs, each drug being applied to previously untreated cells. No doubt the tumour cells undergo changes (for instance in growth kinetics) when transplanted from man to mouse, but it would be surprising if these changes generated differences in spectrum of drug response between tumours that in their respective patients had similar drug sensitivities. Xenografts can therefore be a very useful experimental system in which to test this hypothesis.
Some evidence for the individuality of chemosensitivity among human tumour xenografts came from the work of Nowak et al. (1978) . In a study of 10 xenograft lines of colorectal carcinoma treated with each of 8 chemotherapeutic agents, it was found that the responses in terms of in situ growth delay were on the whole poor, but that some tumour lines did relatively well with some drugs. Even actinomycin D and methotrexate, which ranked poorest overall, were the top-ranking drugs with one particular line. Individuality in response of colonic carcinoma xenografts was also seen by Osieka et al. (1977) and by Houghton & Houghton (1978) .
The present work has provided new evidence of this phenomenon. When the analysis of variance in tumour response was restricted to the 4 most effective agents (melphalan, MeCCNU, cis-Pt and adriamycin) there was significant evidence for "interaction". The implication is that each tumour line was showing some individuality in response to these drugs.
No direct comparisons between the results of the laboratory tests and the response of the same tumours in the patient are possible. However, the overall ranking of drugs may be in line with clinical experience. MeCCNU is one of the most effective drugs in the clinical treatment of melanoma (Constanza et al., 1977) and melphalan, used in high doses, is proving moderately effective (McElwain et al., 1979 , and in preparation). Cis-Pt has not been widely used. In keeping with the in vivo survival data, adriamycin is inactive in clinical melanoma (Sieper et al., 1975) .
The translation ofinformation on chemosensitivity from a short-term laboratory test to clinical practice must take into account the drug schedule>s that are in clinical uise. Where infrequent large doses are used the results of an in vitro test could give valuable information. With drugs such as methotrexate that are given by infusion or in protracted schedules the test will be less useful, and may underestimate the clinical effectiveness of a drug. The other major difficulty with in vitro chemosensitivity tests is the danger of wrongly evaluating drugs that are metabolised in vivo and thereby inactivated or transformed into metabolites that are more active than the parent drug. Our use of the "ADC exposure" assay is intended to alleviate this problem, and the detailed results will be described elsewhere. With experience, we would expect to learn that certain drugs are over-or under-rated by an in vitro test, and modify accordingly the concentration at which sensitivity should be evaluated.
The present work is regarded as a modest step towards the validation and development of in vitro chemosensitivity tests for human tumours. The results are encouraging, but they demonstrate the need for more detailed pharmacokinetic studies and for direct comparisons of the laboratory tests with the response of patients.
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